SCHEDULE 13G: Decheng Capital Funds Disclose Significant Passive Stake in Aardvark Therapeutics

Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and affiliated entities, including Dr. Xiangmin Cui, have disclosed a combined passive beneficial ownership of 18.3% in Aardvark Therapeutics, Inc.

Summary

• Decheng Capital Global Life Sciences Fund IV, L.P. (Fund IV) and Decheng Capital Global Healthcare Fund (Master), LP (Healthcare), along with their general partners and Dr. Xiangmin Cui, have filed a Schedule 13G with the SEC.
• The filing indicates beneficial ownership of Aardvark Therapeutics, Inc. common stock, par value $0.00001 per share, with CUSIP Number 0029421007.
• Fund IV beneficially owns 2,958,887 shares, representing 13.8% of the class of common stock.
• Healthcare beneficially owns 958,412 shares, representing 4.5% of the class of common stock.
• Dr. Xiangmin Cui, through his role as manager of Decheng Capital Management IV (Cayman), LLC (general partner of Fund IV) and indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC (general partner of Healthcare), beneficially owns an aggregate of 3,917,299 shares, representing 18.3% of the class.
• The percentage of class is based upon 21,384,377 shares of Aardvark Therapeutics' common stock outstanding as of February 21, 2025, as reported in the Issuer's prospectus dated February 12, 2025.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Slightly positive. The disclosure of a significant passive stake by a specialized institutional investor like Decheng Capital can be interpreted as a vote of confidence in Aardvark Therapeutics, although it does not imply active involvement in management or strategy.

Positives

• The disclosure of a significant institutional investment by Decheng Capital, a specialized life sciences fund, may be viewed as a vote of confidence in Aardvark Therapeutics' prospects.
• The stated passive nature of the investment suggests a long-term holding strategy rather than an activist intent, which can provide stability.

Risks

• The reporting persons explicitly disclaim status as a 'group' for purposes of this Schedule 13G, which is a common legal disclaimer to avoid certain regulatory implications associated with coordinated control.

Future Outlook

The Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance, strategic direction, or operational outlook.

Management Comments

• The filing includes a certification signed by Xiangmin Cui, as Manager of Decheng Capital Management IV (Cayman), LLC and Decheng Capital LLC, stating that 'the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing reflects a significant investment by a specialized life sciences venture capital firm in a biotechnology company. Such investments are common in the biotech sector, where specialized funds often take substantial, albeit passive, stakes in promising early-stage or clinical-stage companies, providing capital and signaling confidence in the sector's growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by Decheng Capital may be viewed positively, signaling institutional confidence in Aardvark Therapeutics. It also clarifies the ownership structure and control relationships among the reporting entities, providing transparency.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Aardvark Therapeutics, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Keywords

Aardvark Therapeutics, Decheng Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Life Sciences, Passive Investment